文献速递临床试验与 GCP基础与转化研究

EPURE 肾移植试验:依普利酮在肾移植受者中的随机对照试验方案

EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-10-30

EPURE 试验为多中心、双盲、安慰剂对照随机对照试验,计划纳入 132 例接受扩展标准供者(ECD)单肾或双肾移植的血液透析患者,1:1 随机接受依普利酮 25 mg 每 12 小时共 4 天(首剂于移植前给予)或安慰剂。主要结局为 3 个月时用碘海醇清除率测定的 GFR;次要结局包括透析依赖或 GFR<30、移植物功能分类、蛋白尿、高钾血症、住院时长及活检证实的急性排斥。

要点

  • ECD 肾移植受者移植早期给予依普利酮,旨在预防缺血再灌注损伤并改善中期移植物功能。
  • 主要结局为 3 个月时碘海醇清除率测定的 GFR(mL/min/1.73m2)。
  • 试验同时评估安全性,重点是移植后第一周高钾血症的发生。

核心结论

  • EPURE 试验旨在评估 ECD 肾移植受者早期使用盐皮质激素受体拮抗剂(MRA)依普利酮对中期移植物功能的影响及安全性。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机对照试验,计划随机 132 例接受 ECD 单肾或双肾移植的血液透析患者。
  • 纳入患者按 1:1 随机接受依普利酮 25 mg 每 12 小时共 4 天(首剂于肾移植前给予)或安慰剂。

主要发现

  • 原文为研究方案,未报告试验结果。

关键数值与推荐

  • 主要结局为移植后 3 个月时通过碘海醇清除率测定的 GFR(mL/min/1.73m2)。
  • 次要结局包括 3 个月时透析依赖或 GFR<30 mL/min/1.73m2 的比例、即刻/缓慢/延迟移植物功能的比例、3 个月蛋白尿、移植后第一周高钾血症、住院时长及 3 个月内活检证实的急性排斥。
  • 还将通过国家器官受者数据库收集 1、3、10 年的估算 GFR、移植物和患者生存。

临床怎么用

  • 该方案提示对 ECD 肾移植受者可在移植早期试用 MRA 以减轻缺血再灌注损伤,但须密切监测高钾血症。

局限性

  • 原文未报告研究结果,尚不能评价依普利酮的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in immunosuppressive therapy, kidney graft survival has failed to improve during the last decades. Ischemia/reperfusion injury (IRI) is one of the main pathophysiological mechanisms underlying delayed graft function, which is associated with poor long-term graft survival. Due to organ shortage, the proportion of grafts from expanded criteria donors (ECDs) is ever growing. These grafts may particularly benefit from IRI prevention. In preclinical models, mineralocorticoid receptor antagonists (MRAs) have been shown to efficiently prevent IRI. This study aims to assess the effect of MRA administration in the early phase of kidney transplantation (KT) among recipients of ECD grafts on mid-term graft function. METHODS/DESIGN: This is a multicenter, double-blind, placebo-controlled, randomized clinical trial. Patients on hemodialysis and undergoing a single or a dual KT from an ECD will be eligible for inclusion. We plan to randomize 132 patients. Included patients will be randomized (1:1) to receive either eplerenone 25 mg every 12 h during 4 days (the first dose being administered just prior to KT) or placebo. The primary outcome is graft function at 3 months, assessed by glomerular filtration rate (GFR, in mL/min/1.73m2) measured using iohexol clearance. Secondary outcomes include (1) proportion of patients with either dialysis dependency or a GFR < 30 mL/min/1.73m2 at 3 months, (2) proportion of patients with immediate, slow, or delayed graft function, (3) proteinuria at 3 months, (4) occurrence of hyperkalemia during the first week following KT, (5) length of hospital stay for the KT, and (6) occurrence of biopsy-proven acute rejection in the first 3 months following KT. Estimated GFR, graft, and patient survival will also be collected at 1, 3, and 10 years via the national database of organ recipients. DISCUSSION: Improvement of ECD grafts is a public health priority, since better ECD outcomes could eventually limit organ shortage. MRA administration in the early phase of KT may prevent IRI and subsequently improve mid-term graft function. The trial will also assess the safety of MRA administration in this population, primarily the absence of threatening hyperkalemia. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02490904 . Registered on 1 July 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Girerd S, Frimat L, Ducloux D, et al. EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30376884. doi:10.1186/s13063-018-2956-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。